Learn more

CELL and GENE THERAPY Ltd

Overview
  • Total Patents
    36
  • GoodIP Patent Rank
    43,009
  • Filing trend
    ⇧ 750.0%
About

CELL and GENE THERAPY Ltd has a total of 36 patent applications. It increased the IP activity by 750.0%. Its first patent ever was published in 2016. It filed its patents most often in Russian Federation, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are SKAU APS, AN YIHUA and CHENGDU TECBOND BIOLOGICAL PRODUCTS CO LTD.

Patent filings per year

Chart showing CELL and GENE THERAPY Ltds patent filings per year from 1900 to 2020

Focus industries

Top inventors

# Name Total Patents
#1 Savelieva Natalia 36
#2 Gamolski Anton 9
#3 Lazarev Vasilij Nikolaevich 1
#4 Lekhin Vsevolod Petrovich 1
#5 Shmarina Galina Vasilevna 1

Latest patents

Publication Filing date Title
WO2020130878A1 Gene therapy dna vector based on gene therapy dna vector vtvaf17
WO2020130879A1 Gene therapy dna vector
RU2715314C1 VTvaf17-Act1-Cas9 GENE-THERAPEUTIC DNA VECTOR BASED ON VTvaf17 GENE-THERAPEUTIC DNA VECTOR CARRYING TARGET Cas9 GENE FOR HETEROLOGOUS EXPRESSION OF THIS TARGET GENE IN PLANT CELLS DURING GENOME EDITING OF PLANTS, METHOD OF PRODUCING AND USING GENE-THERAPEUTIC DNA VECTOR, STRAIN OF ESCHERICHIA COLI SCS110-AF/VTvaf17-Act1-Cas9 CARRYING GENE-THERAPEUTIC DNA VECTOR, METHOD FOR PREPARING THEREOF, METHOD FOR INDUSTRIAL PRODUCTION OF GENE-THERAPEUTIC DNA VECTOR
RU2730664C2 Gene-therapeutic dna-vector based on gene-therapeutic dna-vector vtvaf17, carrying target gene selected from group of genes ang, angpt1, vegfa, fgf1, hif1α, hgf, sdf1, klk4, pdgfc, prok1, prok2 to increase expression level of said target genes, method for production and use thereof, strain escherichia coli scs110-af/vtvaf17-ang, or escherichia coli scs110-af/vtvaf17-angpt1, or escherichia coli scs110-af/vtvaf17-vegfa, or escherichia coli scs110-af/vtvaf17-fgf1, or escherichia coli scs110-af/vtvaf17-hif1α, or escherichia coli scs110-af/vtvaf17-hgf, or escherichia coli scs110-af/vtvaf17-sdf1, or escherichia coli scs110-af/vtvaf17-klk4, or escherichia coli scs110-af/vtvaf17-pdgfc, or escherichia coli scs110-af/vtvaf17-prok1, or escherichia coli scs110-af/vtvaf17-prok2, carrying gene-therapeutic dna vector, method for production thereof, method for industrial production of gene-therapeutic dna vector
RU2730661C2 Gene-therapeutic dna-vector based on gene-therapeutic dna-vector vtvaf17, carrying target gene selected from group of genes col1a1, col1a2, p4ha1, p4ha2, col7a1, clca2, eln, plod1 to increase level of expression of said target genes, method for production and use thereof, strain escherichia coli scs110-af/vtvaf17-col1a1, or escherichia coli scs110-af/vtvaf17-col1a2, or escherichia coli scs110-af/vtvaf17-p4ha1, or escherichia coli scs110-af/vtvaf17-p4ha2, or escherichia coli scs110-af/vtvaf17-col7a1, or escherichia coli scs110-af/vtvaf17-clca2, or escherichia coli scs110-af/vtvaf17-eln, or escherichia coli scs110-af/vtvaf17- plod1, carrying gene-therapeutic dna vector, method for production thereof, method for industrial production of gene-therapeutic dna vector
RU2730663C2 Gene-therapeutic dna-vector based on gene-therapeutic dna-vector vtvaf17, carrying target gene cas9 for heterologous expression of this target gene in human and animal cells in implementing various methods of genomic editing, method of producing and using gene-therapeutic dna vector, escherichia coli scs110-af/vtvaf17-cas9 strain, carrying gene-therapeutic dna vector, method for preparing thereof, method for production on industrial scale of gene-therapeutic dna vector
RU2730667C2 Gene-therapeutic dna-vector based on gene-therapeutic dna-vector vtvaf17, carrying target gene selected from group of genes krt5, krt14, lamb3, col7a1, to increase level of expression of these target genes, method for production and use thereof, strain escherichia coli scs110-af/vtvaf17-krt5, or escherichia coli scs110-af/vtvaf17-krt14, or escherichia coli scs110-af/vtvaf17-lamb3, or escherichia coli scs110-af/vtvaf17-col7a1, carrying gene-therapeutic dna vector, method for production thereof, method for industrial production of gene-therapeutic dna vector
RU2732479C2 Gene-therapeutic dna-vector based on the gene-therapeutic dna-vector vtvaf17, carrying the target gene selected from a group of genes bdnf, vegfa, bfgf, ngf, gdnf, nt3, cntf, igf1, to increase expression level of said target genes, method for production and use thereof, a strain escherichia coli scs110-af/vtvaf17-bdnf, or escherichia coli scs110-af/vtvaf17-vegfa, or escherichia coli scs110-af/vtvaf17-bfgf, or escherichia coli scs110-af/vtvaf17-ngf, or escherichia coli scs110-af/vtvaf17-gdnf, or escherichia coli scs110-af/vtvaf17-nt3, or escherichia coli scs110-af/vtvaf17-cntf, or escherichia coli scs110-af/vtvaf17-igf1, carrying a gene-therapeutic dna vector, method for production thereof, a method for industrial production of a gene-therapeutic dna vector
RU2720521C1 Gene-therapy dna-vector based on gene-therapy dna-vector vtvaf17, carrying target gene selected from group of genes bmp-2, bmp-7, lmp-1, nell-1 to increase expression level of these target genes, method for production and application thereof, strain escherichia coli scs110-af/vtvaf17-bmp-2, or escherichia coli scs110-af/vtvaf17-bmp-7, or escherichia coli scs110-af/vtvaf17-lmp-1, or escherichia coli scs110-af/vtvaf17-nell-1, carrying gene-therapy dna vector, method for production thereof, method for industrial production of gene-therapy dna vector
RU2720376C1 Gene-therapy dna-vector based on gene-therapy dna-vector vtvaf17, carrying target gene selected from group of genes il11, lif, dicer, hoxa10, wt1, to increase expression level of these target genes, method for production and use thereof, strain escherichia coli scs110-af/vtvaf17-il11, or escherichia coli scs110-af/vtvaf17-lif, or escherichia coli scs110-af/vtvaf17-dicer, or escherichia coli scs110-af/vtvaf17-hoxa10, or escherichia coli scs110-af/vtvaf17-wt1, carrying gene-therapeutic dna vector, method for production thereof, method for industrial production of gene-therapeutic dna vector
RU2720519C1 Gene therapy dna-vector based on gene therapy dna-vector vtvaf17, carrying target gene selected from group of ifnb1, ifna14, ifna2, il12a, il12b genes to increase level of expression of these target genes, method for preparation and use thereof, strain escherichia coli scs110-af/vtvaf17-ifnb1, or escherichia coli scs110-af/vtvaf17-ifna14, or escherichia coli scs110-af/vtvaf17-ifna2, or escherichia coli scs110-af/vtvaf17-il12a, or escherichia coli scs110-af/vtvaf17-il12b, carrying gene-therapeutic dna-vector, method for production thereof, method for industrial production of gene therapy dna vector
RU2705256C1 GENE-THERAPEUTIC DNA VECTOR BASED ON THE GENE-THERAPEUTIC DNA VECTOR VTvaf17, CARRYING THE TARGET GENE SELECTED FROM THE GROUP OF SKI, TGFB3, TIMP2, FMOD GENES TO INCREASE THE LEVEL OF EXPRESSION OF THESE TARGET GENES, A METHOD FOR PREPARING AND USING IT, ESCHERICHIA COLI SCS110-AF/VTvaf17-SKI STRAIN OR ESCHERICHIA COLI SCS110-AF/VTvaf17-TGFB3 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-TIMP2 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-FMOD, CARRYING A GENE-THERAPEUTIC DNA VECTOR, A METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA VECTOR
RU2707537C1 GENE-THERAPEUTIC DNA-VECTOR BASED ON THE GENE-THERAPEUTIC DNA-VECTOR VTvaf17, CARRYING THE TARGET GENE SELECTED FROM THE GROUP OF GENES COL1A1, COL1A2, BMP2, BMP7, TO INCREASE THE LEVEL OF EXPRESSION OF THESE TARGET GENES, METHOD FOR PRODUCTION AND USE THEREOF, ESCHERICHIA COLI SCS110-AF/VTvaf17-COL1A1 STRAIN OR ESCHERICHIA COLI SCS110-AF/VTvaf17-COL1A2 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-BMP2 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-BMP7, CARRYING A GENE-THERAPEUTIC DNA VECTOR, METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA-VECTOR
RU2705252C1 GENE-THERAPEUTIC DNA VECTOR BASED ON THE GENE-THERAPEUTIC DNA VECTOR VTvaf17, CARRYING THE TARGET GENE CFTR, OR NOS1, OR AQ1, OR AQ3, OR AQ5, FOR TREATING DISEASES ASSOCIATED WITH THE NEED TO INCREASE THE LEVEL OF EXPRESSION OF THESE TARGET GENES, A METHOD FOR PRODUCING AND USING IT, ESCHERICHIA COLI SCS110-AF/VTvaf17-CFTR STRAIN, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-NOS1, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-AQ1, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-AQ3, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-AQ5, CARRYING A GENE-THERAPEUTIC DNA VECTOR, METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA VECTOR
RU2700649C2 Genetic construct based on non-viral vector plasmid including p4na2 gene cdna for reducing manifestations of human body conditions associated with reduced expression of p4na2 gene and/or reducing amount of prolyl 4-hydroxy acid alpha 2 protein, method of producing and use
RU2678756C1 Vtvaf17 gene-therapy dna vector, method for producing thereof, escherichia coli scs110-af strain, method for producing thereof, escherichia coli scs110-af/vtvaf17 strain, bearing vtvaf17 gene-therapy dna vector, method for producing thereof
RU2649820C2 Agent for correction of pathological states of cells and tissues and/or organs and human tissue based on col1a2 gene, related to quantitative decrease of protein of collagen type i alpha 2 chain
RU2651758C2 Means for correction of pathological conditions of cells of organs and tissues and/or human organs and tissues, based on the gene of gpx3, related to oxidative stress, method of obtaining and using
RU2652350C2 Line of biologically active gene therapy substances based on col1a1 gene for correction of pathological states of cells of organs and tissues and human organs and tissues, method of obtaining and using
RU2652351C2 Line of biologically active gene-therapy substances based on tgfbr2 gene for correction of pathological states of cells of organs and tissues and human organs and tissues, method of obtaining and using